HBV感染是世界性公共健康问题,在亚太地区尤为严重.目前各乙型肝炎相关防治指南推荐的一线抗病毒药物主要以恩替卡韦、替诺福韦、聚乙二醇干扰素为主,但由于各国家/地区的政策、经济水平、医保覆盖范围以及医疗卫生水平的差异,导致抗病毒治疗的方案各不相同.希望通过建立乙型肝炎长期随访队列,比较乙型肝炎不同治疗方案,进一步提高乙型肝炎治愈率,降低肝硬化、肝癌和终末期肝病的发生.并通过真实世界队列研究数据,充分了解指南与实践的差距,为指南的制订与规范提供参考,且还能够平衡临床疗效和成本效益.%Hepatitis B virus (HBV) infection is a global public health issue,especially in the Asian-Pacific region.At present,entecavir,tenofovir,and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B;however,different national/regional policies,economic level,coverage of health insurance,and medical level have caused the difference in antiviral regimens.Therefore,we have established a long-term follow-up cohort of hepatitis B to evaluate the efficacy of different treatment regimens,in order to improve the cure rate of hepatitis B and reduce the incidence rates of liver cirrhosis,liver cancer,and end-stage liver disease.Real-world data from cohort study help to understand the differences between guidelines and clinical practice,provide a reference for HBV guidelines,and balance clinical effect and cost-effectiveness.
展开▼
